FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106399435> ?p ?o ?g. }

• W2106399435 endingPage "257" @default.
• W2106399435 startingPage "249" @default.
• W2106399435 abstract "To assess the efficacy and safety of duloxetine in women with stress urinary incontinence.Randomised double-blind, placebo-controlled clinical trial.Fort-six centres in seven European countries and Canada.Four hundred and ninety-four women aged 24-83 years identified as having predominant symptoms of stress urinary incontinence using a clinical algorithm that was 100% predictive of urodynamic stress urinary incontinence in a subgroup of 34 women.The case definition included a predominant symptom of stress urinary incontinence with a weekly incontinence episode frequency > or =7, the absence of predominant symptoms of urge incontinence, normal diurnal and nocturnal frequencies, a bladder capacity > or =400 mL and both a positive cough stress test and positive stress pad test. Subjects completed two urinary diaries prior to randomisation and three diaries during the active treatment phase of the study, each completed during the week prior to monthly visits. Subjects also completed quality of life questionnaires at each visit. Safety was assessed by the evaluation of treatment-emergent adverse events, discontinuation of treatment because of adverse events, serious adverse events, vital sign measurements, electrocardiograms (ECG) and clinical laboratory tests.After a two-week placebo lead-in, women received placebo or duloxetine 40 mg BD for 12 weeks.The percentage decrease in incontinence episode frequency and the change in the Incontinence Quality of Life (I-QOL) questionnaire total score were prespecified as co-primary outcome variables in the protocol.Incontinence episode frequency decreased significantly with duloxetine compared with placebo (median decrease of 50%vs 29%; P= 0.002) with comparable improvements in the more severely incontinent subgroup (those experiencing at least 14 incontinence episodes per week at baseline; 56%vs 27% decreases; P < 0.001). The primary analysis of I-QOL scores did not reveal a significant difference between treatment groups, due primarily to the carrying forward of low scores from patients who discontinued treatment very early due to duloxetine-associated adverse events. The increase in I-QOL scores was significantly greater for duloxetine than for placebo at each of the three postrandomisation visits after 4, 8, and 12 weeks of treatment. Discontinuation rates for adverse events were higher for duloxetine (22%vs 5%; P < 0.001) with nausea being the most common reason for discontinuation (5.3%). Nausea tended to be mild to moderate, not progressive, and transient.The findings support duloxetine as a potential treatment for women with stress urinary incontinence." @default.
• W2106399435 created "2016-06-24" @default.
• W2106399435 creator A5002038596 @default.
• W2106399435 creator A5021212875 @default.
• W2106399435 creator A5025714543 @default.
• W2106399435 creator A5031133453 @default.
• W2106399435 creator A5039271306 @default.
• W2106399435 creator A5042148787 @default.
• W2106399435 creator A5090459217 @default.
• W2106399435 date "2004-01-21" @default.
• W2106399435 modified "2023-10-15" @default.
• W2106399435 title "Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence" @default.
• W2106399435 cites W1967312126 @default.
• W2106399435 cites W1980067374 @default.
• W2106399435 cites W1985799577 @default.
• W2106399435 cites W1993057480 @default.
• W2106399435 cites W1994953553 @default.
• W2106399435 cites W2010882816 @default.
• W2106399435 cites W2017829997 @default.
• W2106399435 cites W2018425549 @default.
• W2106399435 cites W2024520777 @default.
• W2106399435 cites W2034833489 @default.
• W2106399435 cites W2064865346 @default.
• W2106399435 cites W2066288167 @default.
• W2106399435 cites W2073416662 @default.
• W2106399435 cites W2081812660 @default.
• W2106399435 cites W2115562984 @default.
• W2106399435 cites W2124733814 @default.
• W2106399435 cites W2150242878 @default.
• W2106399435 cites W2161853504 @default.
• W2106399435 cites W2441438395 @default.
• W2106399435 doi "https://doi.org/10.1111/j.1471-0528.2004.00067.x" @default.
• W2106399435 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14961887" @default.
• W2106399435 hasPublicationYear "2004" @default.
• W2106399435 type Work @default.
• W2106399435 sameAs 2106399435 @default.
• W2106399435 citedByCount "194" @default.
• W2106399435 countsByYear W21063994352012 @default.
• W2106399435 countsByYear W21063994352013 @default.
• W2106399435 countsByYear W21063994352014 @default.
• W2106399435 countsByYear W21063994352015 @default.
• W2106399435 countsByYear W21063994352016 @default.
• W2106399435 countsByYear W21063994352017 @default.
• W2106399435 countsByYear W21063994352018 @default.
• W2106399435 countsByYear W21063994352019 @default.
• W2106399435 countsByYear W21063994352020 @default.
• W2106399435 countsByYear W21063994352021 @default.
• W2106399435 countsByYear W21063994352022 @default.
• W2106399435 countsByYear W21063994352023 @default.
• W2106399435 crossrefType "journal-article" @default.
• W2106399435 hasAuthorship W2106399435A5002038596 @default.
• W2106399435 hasAuthorship W2106399435A5021212875 @default.
• W2106399435 hasAuthorship W2106399435A5025714543 @default.
• W2106399435 hasAuthorship W2106399435A5031133453 @default.
• W2106399435 hasAuthorship W2106399435A5039271306 @default.
• W2106399435 hasAuthorship W2106399435A5042148787 @default.
• W2106399435 hasAuthorship W2106399435A5090459217 @default.
• W2106399435 hasConcept C126322002 @default.
• W2106399435 hasConcept C126894567 @default.
• W2106399435 hasConcept C142724271 @default.
• W2106399435 hasConcept C159110408 @default.
• W2106399435 hasConcept C1862650 @default.
• W2106399435 hasConcept C197934379 @default.
• W2106399435 hasConcept C204787440 @default.
• W2106399435 hasConcept C27081682 @default.
• W2106399435 hasConcept C2777912814 @default.
• W2106399435 hasConcept C2778531004 @default.
• W2106399435 hasConcept C2778715236 @default.
• W2106399435 hasConcept C2778941218 @default.
• W2106399435 hasConcept C2779523193 @default.
• W2106399435 hasConcept C2779951463 @default.
• W2106399435 hasConcept C2780764818 @default.
• W2106399435 hasConcept C535046627 @default.
• W2106399435 hasConcept C71924100 @default.
• W2106399435 hasConceptScore W2106399435C126322002 @default.
• W2106399435 hasConceptScore W2106399435C126894567 @default.
• W2106399435 hasConceptScore W2106399435C142724271 @default.
• W2106399435 hasConceptScore W2106399435C159110408 @default.
• W2106399435 hasConceptScore W2106399435C1862650 @default.
• W2106399435 hasConceptScore W2106399435C197934379 @default.
• W2106399435 hasConceptScore W2106399435C204787440 @default.
• W2106399435 hasConceptScore W2106399435C27081682 @default.
• W2106399435 hasConceptScore W2106399435C2777912814 @default.
• W2106399435 hasConceptScore W2106399435C2778531004 @default.
• W2106399435 hasConceptScore W2106399435C2778715236 @default.
• W2106399435 hasConceptScore W2106399435C2778941218 @default.
• W2106399435 hasConceptScore W2106399435C2779523193 @default.
• W2106399435 hasConceptScore W2106399435C2779951463 @default.
• W2106399435 hasConceptScore W2106399435C2780764818 @default.
• W2106399435 hasConceptScore W2106399435C535046627 @default.
• W2106399435 hasConceptScore W2106399435C71924100 @default.
• W2106399435 hasIssue "3" @default.
• W2106399435 hasLocation W21063994351 @default.
• W2106399435 hasLocation W21063994352 @default.
• W2106399435 hasOpenAccess W2106399435 @default.
• W2106399435 hasPrimaryLocation W21063994351 @default.
• W2106399435 hasRelatedWork W1983402052 @default.
• W2106399435 hasRelatedWork W2048717762 @default.

• next